Article
Abstracts are due by September 15, 2015.
Abstracts are due by September 15, 2015.
The Patient Access Network (PAN) Foundation has issued a Call for Case Studies that addresses:
Case Studies will be designed to address one or more of the following questions:
This Call for Case Studies is being conducted in conjunction with the launch of the “PAN Challenge: Balancing Moral Hazard, Affordability and Access to Critical Therapies in the Age of Cost Sharing,” a joint initiative of the PAN Foundation and The American Journal of Managed Care. The PAN Challenge consists of a call for abstracts/papers that propose policy solutions for improving access to critical treatments for people with rare and chronic illnesses.
For more information about the PAN Challenge, visit www.panfoundation.org/challenge.
How to submit
Abstracts describing your organization’s Case Study must be submitted by September 15, 2015. Abstracts should be no more than 250 words and submitted directly to Amy Niles, Director, Alliance Development, at aniles@panfoundation.org. Collaborations between organizations are encouraged.
Organizations will be notified of whether their abstracts have been accepted by October 1, 2015.
Accepted organizations will be asked to submit case studies by December 15, 2015. Case Studies should be no more than 2,500 words. Case Studies should be submitted directly to Amy Niles ataniles@panfoundation.org.
By January 15, 2016, selected organizations will be invited to present their Case Studies at the Cost-Sharing Roundtable, to be hosted by the PAN Foundation and The American Journal of Managed Care in Washington, DC, mid-February 2016 (specific date to be determined). The PAN Foundation will pay for transportation and lodging for one person to attend the Roundtable to present their Case Study.
Selected Case Studies will be published in a future print and online supplemental edition of The American Journal of Managed Care. Selected Case Studies will also be promoted on PAN’s web site and publications.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa